[2018 new recommendations for dyslipidemia : a critical review of evidence]

Area of Science:

• Cardiology
• Endocrinology
• Preventive Medicine

Background:

• Dyslipidemia is a significant risk factor for cardiovascular disease.
• Individualized patient management is crucial, considering comorbidities and overall cardiovascular risk.
• Current treatment strategies aim to avoid over-treatment while effectively managing lipid levels.

Purpose of the Study:

• To present the recent recommendations from the Swiss Atherosclerosis Association (AGLA) for managing dyslipidemia.
• To integrate evidence from recent studies into clinical practice guidelines.
• To emphasize a personalized approach to dyslipidemia management, focusing on cardiovascular risk stratification.

Main Methods:

• Review of recent scientific literature and clinical studies on dyslipidemia.
• Analysis of the PROCAM score for cardiovascular risk assessment.
• Incorporation of the latest AGLA guidelines for dyslipidemia management.
• Consideration of lifestyle interventions and secondary causes of dyslipidemia.

Main Results:

• Cardiovascular risk is categorized into low, moderate, and high.
• Lifestyle interventions are the primary therapy for most patients in primary prevention.
• Exclusion of secondary etiologies is essential, as their treatment can resolve lipid abnormalities.
• Familial dyslipidemia requires specific management due to its high associated cardiovascular risk.

Conclusions:

• Individualized dyslipidemia management based on cardiovascular risk is paramount.
• Lifestyle modifications and addressing secondary causes are foundational therapeutic strategies.
• New AGLA recommendations aim for optimized patient care and avoidance of over-therapizing dyslipidemia.